| Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression KS Antman, JD Griffin, A Elias, MA Socinski, L Ryan, SA Cannistra, ... New England Journal of Medicine 319 (10), 593-598, 1988 | 848 | 1988 |
| Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized … GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ... Journal of Clinical Oncology 34 (8), 786, 2016 | 817 | 2016 |
| Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020 | 748 | 2020 |
| Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man MA Socinski, A Elias, L Schnipper, SA Cannistra, KH Antman, JD Griffin The Lancet 331 (8596), 1194-1198, 1988 | 731 | 1988 |
| Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial WD Tap, RL Jones, BA Van Tine, B Chmielowski, AD Elias, D Adkins, ... The Lancet 388 (10043), 488-497, 2016 | 659 | 2016 |
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas RG Maki, DR D'Adamo, ML Keohan, M Saulle, SM Schuetze, SD Undevia, ... Journal of Clinical Oncology 27 (19), 3133, 2009 | 651 | 2009 |
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane HJ Burstein, AD Elias, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, ... Journal of Clinical Oncology 26 (11), 1810-1816, 2008 | 638 | 2008 |
| An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. K Antman, J Crowley, SP Balcerzak, SE Rivkin, GR Weiss, A Elias, ... Journal of clinical oncology 11 (7), 1276-1285, 1993 | 605 | 1993 |
| Adaptive randomization of veliparib–carboplatin treatment in breast cancer HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ... New England Journal of Medicine 375 (1), 23-34, 2016 | 583 | 2016 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 532 | 2020 |
| Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology WJ Gradishar, MS Moran, J Abraham, R Aft, D Agnese, KH Allison, ... Journal of the National Comprehensive Cancer Network 20 (6), 691-722, 2022 | 468 | 2022 |
| NCCN guidelines insights: breast cancer, version 1.2017 WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the national comprehensive cancer network 15 (4), 433-451, 2017 | 467 | 2017 |
| Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide DR Cochrane, S Bernales, BM Jacobsen, DM Cittelly, EN Howe, ... Breast Cancer Research 16, 1-19, 2014 | 440 | 2014 |
| A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard … K Antman, L Ayash, A Elias, C Wheeler, M Hunt, JP Eder, BA Teicher, ... Journal of clinical oncology 10 (1), 102-110, 1992 | 433 | 1992 |
| Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018 | 425* | 2018 |
| Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without … PG Richardson, C Murakami, Z Jin, D Warren, P Momtaz, D Hoppensteadt, ... Blood, The Journal of the American Society of Hematology 100 (13), 4337-4343, 2002 | 391 | 2002 |
| Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ... Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016 | 369 | 2016 |
| Adaptive randomization of neratinib in early breast cancer JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ... New England Journal of Medicine 375 (1), 11-22, 2016 | 358 | 2016 |
| Male breast cancer: a disease distinct from female breast cancer A Gucalp, TA Traina, JR Eisner, JS Parker, SR Selitsky, BH Park, AD Elias, ... Breast cancer research and treatment 173, 37-48, 2019 | 342 | 2019 |
| Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. A Elias, L Ryan, A Sulkes, J Collins, J Aisner, KH Antman Journal of Clinical Oncology 7 (9), 1208-1216, 1989 | 339 | 1989 |
